Single-product dependence
Most commercial revenue is tied to XDEMVY, so any slowdown would materially affect results.
- Scope
- Commercial sales concentration
- Materiality
- high
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing ophthalmic and other specialty therapeutics built around lotilaner and related formulations. Its business combines a marketed eye-care product, XDEMVY, with a pipeline that includes product candidates for ocular rosacea and Lyme disease prophylaxis.
−15,5 %
−14,7 %
+146,7 %
3.85
3.82
| % | |
|---|---|
| Commercial ophthalmology product | 85% Approved prescription eye-care therapy sold for Demodex blepharitis. |
| Clinical-stage ophthalmology pipeline | 10% Development programs for ocular rosacea and related eye conditions. |
| Licensing and collaboration revenue | 5% Revenue from out-licensing and clinical supply arrangements. |
Tarsus sells primarily to eye care professionals who prescribe XDEMVY for patients with Demodex blepharitis...
- Eye care professionalsprimary
Ophthalmologists and optometrists prescribe XDEMVY and drive adoption through diagnosis and treatment decisions.
- Patients with Demodex blepharitisprimary
Patients buy the therapy through prescriptions to treat a specific eyelid condition and related symptoms.
- Payers and covered livesprimary
Commercial insurers, Medicare, and Medicaid affect formulary access and out-of-pocket affordability.
- Pharmacy and distribution partnerssecondary
Specialty and dispensing channels fulfill prescriptions and support commercial reach.
- Clinical trial and future specialty prescribersemerging
Specialists who may adopt TP-04 or TP-05 if those programs reach approval.
Tarsus is headquartered in the United States and generates most of its commercial activity there through XDEMVY...
- •United States is the core commercial market for XDEMVY
- •China contributes collaboration revenue through an out-license
- •Third-party manufacturing and supply chain partners are partly offshore
- •U.S. payer coverage is important for prescription access and uptake
- •International supply and regulatory dependencies affect commercialization
Tarsus is focused on expanding XDEMVY adoption in Demodex blepharitis while maintaining regulatory, manufacturing, and...
01
Grow XDEMVY commercial adoptionshort-term
The approved product is the main revenue engine and validates the category.
02
Advance the pipelinemedium-term
Additional approved products would diversify revenue and reduce single-product dependence.
03
Secure supply chain and manufacturing capacityshort-term
Commercial continuity depends on reliable lotilaner supply and drug product manufacturing.
04
Protect intellectual property and partnering optionalitylong-term
Patent and licensing strength support pricing power and future collaboration value.
Tarsus is exposed to single-product concentration, clinical development risk, and dependence on third-party...
Clinical development failure
TP-04 and TP-05 are still in development and may not show sufficient efficacy or safety.
- Scope
- Pipeline programs
- Materiality
- high
Manufacturing and supplier concentration
The company has relied on a limited number of suppliers and CMOs for lotilaner and drug product.
- Scope
- API and fill-finish supply
- Materiality
- high
Reimbursement and access risk
Coverage decisions by commercial and government payers affect prescription volume and net sales.
- Scope
- Commercial access
- Materiality
- high
Competitive pressure
Other prescription and off-label treatments can limit market share and pricing power.
- Scope
- Ophthalmology and blepharitis market
- Materiality
- medium
Gross-to-net revenue reserves
Affects reported net product sales and quarterly comparability
Collaboration and license revenue recognition
Can create uneven revenue timing across periods
Inventory and launch-related costs
Can affect margins and working capital
Impairment of development assets
Potential write-downs if programs underperform
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
Traws Pharma, Inc.
TRAW · Pharmaceutical Preparations
PALVELLA THERAPEUTICS, INC.
PVLA · Pharmaceutical Preparations
Palvella Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing QTORIN rapamycin for rare genetic skin and vascular disorders.
Kenvue Inc.
KVUE · Perfumes, Cosmetics & Other Toilet Preparations
XBiotech Inc.
XBIT · Pharmaceutical Preparations
Milestone Pharmaceuticals Inc.
MIST · Pharmaceutical Preparations
: 29/04/2026